MARKET

GLUE

GLUE

Monte Rosa Therapeutics, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.00
-0.15
-0.99%
After Hours: 15.00 0 0.00% 16:04 01/14 EST
OPEN
14.76
PREV CLOSE
15.15
HIGH
15.33
LOW
14.50
VOLUME
188.27K
TURNOVER
--
52 WEEK HIGH
45.56
52 WEEK LOW
14.50
MARKET CAP
697.59M
P/E (TTM)
-9.6283
1D
5D
1M
3M
1Y
5Y
Monte Rosa Therapeutics EPS beats by $0.03
Monte Rosa Therapeutics (NASDAQ:GLUE): Q3 GAAP EPS of -$0.43 beats by $0.03. Cash and cash equivalents as of Sept. 30, 2021, were $367.0 million. Press Release
Seekingalpha · 11/10/2021 14:12
Monte Rosa Therapeutics Q3 EPS $(0.43) Up From $(4.29) YoY
Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly losses of $(0.43) per share. This is a 89.98 percent increase over losses of $(4.29) per share from the same period last year.
Benzinga · 11/10/2021 12:50
BRIEF-Monte Rosa Therapeutics Announces First Development Candidate And Reports Q3 2021 Financial Results
reuters.com · 11/10/2021 12:41
Merck veteran launches immuno-oncology startup with $80M
After more than six years heading up oncology units at Merck & Co. Inc., Zhen Su is leading his own startup to expand into the immuno-oncology space.
American City Business Journals · 11/08/2021 12:00
Monte Rosa Therapeutics To Present At 4th Annual Targeted Protein Degradation Summit
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a biotechnology company developing novel molecular glue precision medicines, today announced that Sharon Townson, Ph.D., Chief Technology Officer, will present at the virtual
Benzinga · 10/20/2021 11:38
SVB Leerink Initiates Coverage On Monte Rosa Therapeutics with Market Perform Rating, Announces Price Target of $20
SVB Leerink analyst Andrew Berens initiates coverage on Monte Rosa Therapeutics (NASDAQ:GLUE) with a Market Perform rating and announces Price Target of $20.
Benzinga · 10/14/2021 11:36
Monte Rosa Therapeutics Presents Preclinical Data at AACR-NCI-EORTC Highlighting Potential of Molecular Glue Degraders for the Treatment of Myc-driven Cancer
Data Demonstrate Novel Link Between GSPT1 and Myc-induced Transcription and Protein TranslationBOSTON, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue-based precision m...
GlobeNewswire · 10/07/2021 13:00
Biotech Company Pasithea Offers Two-Pronged Approach in Psychiatric Treatment
Photo by Dimitri Karastelev on Unsplash
Benzinga · 10/05/2021 12:37
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GLUE. Analyze the recent business situations of Monte Rosa Therapeutics, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

16.67%Strong Buy
66.67%Buy
16.67%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average GLUE stock price target is 33.00 with a high estimate of 40.00 and a low estimate of 20.00.
High40.00
Average33.00
Low20.00
Current 15.00
EPS
Actual
Estimate
-2.90-2.18-1.45-0.73
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 55
Institutional Holdings: 33.43M
% Owned: 71.88%
Shares Outstanding: 46.51M
TypeInstitutionsShares
Increased
6
4.51M
New
28
869.94K
Decreased
13
827.68K
Sold Out
19
1.73M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.51%
Pharmaceuticals & Medical Research
+0.11%
Key Executives
Non-Executive Chairman/Director
Alexander Mayweg
President/Chief Executive Officer/Director
Markus Warmuth
Chief Financial Officer
Ajim Tamboli
Chief Technology Officer
Sharon Townson
Chief Scientific Officer
Owen Wallace
Other
John Castle
Other
Filip Janku
Other
Jullian Jones
Director
Bradley Bolzon
Independent Director
Ali Behbahani
Independent Director
Kimberly Blackwell
Independent Director
Chandra Leo
Independent Director
Andrew Schiff
Independent Director
Christine Siu
No Data
About GLUE
Monte Rosa Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. It develops a protein degradation platform, called QuEEN, that enables it to identify protein targets and molecular glue degrader (MGD), product candidates that are designed to eliminate therapeutically relevant proteins. It focuses on therapeutic targets backed by biological and genetic rationale discovering and developing novel precision medicines. It utilizes its Quantitative and Engineered Elimination of Neosubstrates (QuEEN), platform to design novel MGDs focused on delivering therapies to targets that have been considered undruggable or inadequately drugged in biological pathways across clinical indications in oncology and non-oncology, including immunology, inflammation, neurological and genetic diseases.

Webull offers kinds of Monte Rosa Therapeutics Inc stock information, including NASDAQ:GLUE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GLUE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GLUE stock methods without spending real money on the virtual paper trading platform.